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Monoamine oxidaseAlthough a major contribution to myocardial ischemia–reperfusion (I/R) injury is suggested to be provided
by formation of reactive oxygen species (ROS) within mitochondria, sites and mechanisms are far from being
elucidated. Besides a dysfunctional respiratory chain, other mitochondrial components, such as monoamine
oxidase and p66Shc, might be involved in oxidative stress. In particular, p66Shc has been shown to catalyze the
formation of H2O2. The relationship among p66Shc, ROS production and cardiac damage was investigated by
comparing hearts from p66Shc knockout mice (p66Shc−/−) and wild-type (WT) littermates. Perfused hearts
were subjected to 40 min of global ischemia followed by 15 min of reperfusion. Hearts devoid of p66Shc were
signiﬁcantly protected from I/R insult as shown by (i) reduced release of lactate dehydrogenase in the
coronary efﬂuent (25.7±7.49% in p66Shc−/− vs. 39.58±5.17% in WT); (ii) decreased oxidative stress as
shown by a 63% decrease in malondialdehyde formation and 40±8% decrease in tropomyosin oxidation. The
degree of protection was independent of aging. The cardioprotective efﬁcacy associated with p66Shc ablation
was comparable with that afforded by other antioxidant interventions and could not be increased by
antioxidant co-administration suggesting that p66Shc is downstream of other pathways involved in ROS
formation. In addition, the absence of p66Shc did not affect the protection afforded by ischemic
preconditioning. In conclusion, the absence of p66Shc reduces the susceptibility to reperfusion injury by
preventing oxidative stress. The present ﬁndings provide solid and direct evidence that mitochondrial ROS
formation catalyzed by p66Shc is causally related to reperfusion damage.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Formation of reactive oxygen species (ROS) contributes to many
pathological processes accelerating, or even determining, the evolu-
tion of cell injury toward necrosis or apoptosis [1–6]. Although ROS
formation is also involved in physiological processes [7–9], the
imbalance between their generation and removal that is termed
oxidative stress plays a major role in cardiac diseases, especially in
myocardial injury caused by ischemia and reperfusion (I/R) [10–12]., thiobarbituric acid reactive
nylglycine; MAO, monoamine
xygen species; IPC, ischemic
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ll rights reserved.A large body of evidence supports the concept that ROS are formed
within mitochondria under physiological and pathological conditions
[3,7,13,14]. Although mitochondria are considered the most relevant
site for the formation of reactive oxygen species (ROS) in cardiac
myocytes, a major and unsolved issue is where ROS are generated in
mitochondria.
Respiratory chain is generally indicated as a main site for ROS
formation [3,13]. However, other mitochondrial components are
likely to contribute to ROS generation [5]. Recent reports highlight
the relevance of p66Shc (reviewed in [6,15]). This protein is a splice
variant of p52Shc/p46Shc, two cytoplasmic adaptor proteins involved
in the propagation of intracellular signals from activated tyrosine
kinases to Ras [16]. p66Shc has the same modular structure of
p52Shc/p46Shc (SH2-CH1-PTB) and contains a unique N-terminal
region (CH2); however, it is not involved in Ras regulation, but
rather functions in the intracellular pathway(s) that regulates ROS
metabolism and apoptosis [17–19]. A fraction of p66Shc localizes
within the mitochondrial inter-membrane space where it oxidizes
reduced cytochrome c. As a consequence of the p66Shc-mediated
775A. Carpi et al. / Biochimica et Biophysica Acta 1787 (2009) 774–780oxidation of cytochrome c, molecular oxygen is partially reduced to
peroxide. In mitochondria the H2O2 generated by p66Shc/cyto-
chrome c reaction contributes to the opening of the mitochondrial
permeability transition pore and the triggering of apoptosis [20].
This explains why the genetic ablation of p66Shc results in a
marked reduction of oxidative stress. In fact, reduced ROS levels
have invariably been detected in cells derived from p66Shc knock
out (p66Shc−/−) mice [19–24]. In vivo, p66Shc−/− tissues show less
intracellular and systemic oxidative damage [23,25–27]. In addition,
p66Shc−/− cells are resistant to apoptosis induced by a variety of
different signals, including hydrogen peroxide [19,21], ultraviolet
radiation [18,19], staurosporine [20], growth factor deprivation [19],
calcium ionophore and CD3–CD4 cross-linking [24]. Similarly,
p66Shc−/− mice are resistant to apoptosis induced by paraquat,
hypercholesterolemia and ischemia [18,23,27]. Notably, p66Shc−/−
mice live longer [18] and show signs of retarded aging [23,27].
Numerous studies relate p66Shc to cardiovascular pathophysiol-
ogy (reviewed in [5,28]. Oddly, with the single exception of a study
on hindlimb ischemia [23], ischemic injury has so far attracted
scarce attention and no information is available on the possible
role of p66Shc in the wide spectrum of alterations associated with
myocardial I/R. Here, we show that the susceptibility to I/R injury
is greatly decreased in hearts devoid of p66Shc along with a
marked reduction in oxidative alterations of proteins and lipids.
2. Materials and methods
2.1. Treatment protocols for ischemia studies
All aspects of animal care and experimentation were performed
in accordance with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and Italian regulation
concerning the care and use of laboratory animals and were
approved by the Ethical Committee of the University of Padova.
Adult (aged 4 months) male p66Shc−/− [18] and C57BL/6WTmice
(Charles River, Milan, Italy) were anaesthetized with an intraperito-
neal injection of Zoletil 100 (30 mg/kg). Hearts were perfused with
bicarbonate buffer gassed with 95% O2–5% CO2 at 37 °C (pH 7.4) at a
constant ﬂux of 5 ml/min. Perfusion was performed in the
nonrecirculating Langendorff mode, as previously described [29].
The perfusion buffer contained (in mM) 118.5 NaCl, 3.1 KCl, 1.18
KH2PO4, 25.0 NaHCO3, 1.2 MgCl2, 1.4 CaCl2 and 5.6 glucose. Hearts
were treated as follows (n≥6/group): after 10 min of stabilization,
hearts were subjected to 40 min of global ischemia (I-40) by stopping
the coronary ﬂow and 15 min of reperfusion (R-15) with or without
preceding IPC, which consisted of three episodes of 5 min of ischemia
and 5 min of reperfusion. After reperfusion hearts (n=8) were
quickly immersed into PBS containing 0.5% Triton X100 and homo-
genized for measurement of lactate dehydrogenase (LDH), and hearts
(n=6) were frozen in liquid nitrogen and stored at−80 °C for future
analysis. Treatments were performed adding the MAO inhibitor
pargyline (0.5 mM) or MPG (1 mM) to the perfusion buffer.
2.2. Measurement of lactate dehydrogenase activity
To determine the amount of lactate dehydrogenase (LDH)
released from the hearts exposed to I/R, coronary efﬂuent was
collected at 1 min intervals during the 15 min of reperfusion as
previously described [30]. At the end of reperfusion hearts were
collected and homogenized for assessing the residual activity of
LDH in the whole tissue. LDH activity was determined by means of
a classic procedure [31]. Since all values were normalized to heart
weight, the amount of LDH released was expressed as % of total
(i.e., efﬂuent+homogenate) to rule out possible changes due to
variations in heart size [32].2.3. Measurement of lipid peroxidation
Lipid peroxide level was estimated by thiobarbituric acid (TBA)
reaction with malondialdehyde (MDA), a product formed due to the
peroxidation of membrane lipids [33]. Heart tissues were homo-
genized in 1 ml of 0.15 M KCl and 0.024% butylated hydroxytoluene
(BHT) using motor driven Teﬂon pestle followed by centrifugation of
tissue homogenate at 10,000 g. The supernatant obtained after
centrifugation was added with 0.5 ml of 30% trichloroacetic acid
(TCA) followed by 0.5 ml of 0.8% TBA. After incubation for 1 h at
100 °C, samples were centrifuged at 800 g for 10 min. The absorbance
of supernatant was measured at 535 nm. Results were expressed as
picomoles of TBA reactive substances (TBARS), i.e., essentially
malondialdehyde, per mg of tissue.
2.4. Protein extraction and immunoelectrophoresis
Tropomyosin oxidation was assessed as previously described
[34,35]. Brieﬂy, hearts were stored in liquid nitrogen and then
homogenized in ice-cold PBS, pH 7.2 containing an antiprotease
mixture. Protein samples were loaded on 12% SDS-PAGE separating
gels and then transferred to 0.45 µm pore-size nitrocellulose
membranes (Bio-Rad) The membranes were blocked by incubation
with 3% BSA and then incubated at room temperature with an
anti-tropomyosin monoclonal antibody (CH1 clone, Sigma Chemical
Co.) and revealed by anti-mouse immunoglobulin conjugated with
horseradish peroxidase (Dako, Glostrup, Denmark). Cardiac inter-
stitial and cardiomyocytes were lysed in RIPA buffer and clariﬁed
by centrifugation at 4 °C for 12,000 g for 10 min and boiled with
SDS sample buffer. Western blot analysis was performed as above.
Blots were probed with anti-SHC (BD Transduction Laboratories)
and anti-desmin (Oncogene) antibodies. Protein bands were
detected using anti-mouse immunoglobulin conjugated with horse-
radish peroxidase (Dako, Glostrup, Denmark). Signals were visua-
lized by a chemiluminescence detection system checking that
exposures were within the linear range of detection.
2.5. Immunohistochemistry
The immunohistochemistry analysis was performed as pre-
viously described [35]. Brieﬂy, cryosections were incubated with
anti-tropomyosin monoclonal antibodies (CH1 clone) (1:25 in PBS
containing 0.3% BSA). After several rinses with PBS, sections were
incubated with ﬂuorescein-conjugated secondary antibodies (Dako).
The ﬂuorescence images were acquired with an Olympus IMT-2
inverted microscope, equipped with a xenon lamp and a 12-bit
digital cooled CCD camera (Micromax, Princeton Instruments,
Monmouth Junction, NJ, USA) as previously described. For detection
of the ﬂuorescein ﬂuorescence, 488±25 nm excitation and 522 nm
longpass emission ﬁlter settings were used. Data were acquired and
analyzed using Metamorph software (Universal Imaging, West
Chester, PA, USA).
2.6. Cardiac interstitial cells and cardiomyocytes isolation
Myocytes were separated from cardiac interstitial cells (i.e.,
non-myocytes) as previously described [36]. Brieﬂy, cell dissocia-
tion was obtained by perfusion with collagenase B (1 mg/ml)
(Roche, Milan, Italy) in the absence of added Ca2+ at 37 °C for
10 min. After replacing the enzymatic solution with a 0.25 μM Ca2+
solution the ventricles were minced. Cardiomyocytes were collected
by centrifugation at 200 rpm for 2 min. and the supernatant was
ﬁltered sequentially with 40, 20 and 15 μm nylon mesh. Cardiac
interstitial cells were collected by centrifugation. Contamination of
interstitial cells in myocyte samples was ruled out by assessing
desmin content.
Fig. 1. Myocardial loss of viability induced by post-ischemic reperfusion is reduced in hearts lacking p66Shc. Loss of viability was evaluated as the percentage of total LDH activity
released in the coronary efﬂuent during post-ischemic reperfusion. Hearts isolated from young (4 months) and old (24 months) WT or p66Shc−/−mice were subjected to 40 min of
global ischemia followed by 15 min of reperfusion. To avoid changes due to variations in heart size, LDH activity was assessed in both coronary efﬂuents collected at 1 min intervals
during reperfusion (dashed bars) and tissue homogenates obtained at the end of the perfusion protocols (white bars). The cardioprotective effect associatedwith p66Shc ablationwas
independent of aging. Values are means±S.E. ⁎pb0.05.
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Results are presented as means±SE. Statistical analysis was
performed utilizing the unpaired Student's t-test.
3. Results and discussion
3.1. Hearts isolated from p66Shc−/− mice are protected against loss of
viability induced by post-ischemic reperfusion
Cardioprotective effects elicited by the genetic deletion of
p66Shc were investigated in isolated hearts under conditions of
ischemia and reperfusion. According to well established notion, in
hearts isolated from wild-type (WT) mice the readmission of
coronary ﬂow after 40 min of no ﬂow global ischemia caused a
signiﬁcant loss of viability. Indeed, the release of LDH in the
coronary efﬂuent was paralleled by a decreased activity of this
enzyme in the hearts collected at the end of the perfusion protocol
(Fig. 1). Notably, in hearts isolated from p66Shc−/− mice the degree
of tissue necrosis was largely attenuated. In fact the amount of LDH
released during post-ischemic reperfusion was decreased by 35%
(39.58±5.17% in WT vs. 25.70±7.49% in p66Shc−/−; pb0.05). The
cardioprotective effect associated with the absence of p66Shc was
no longer present when the ischemia duration was longer thanFig. 2. Reperfusion-induced lipoperoxidation is blunted in p66Shc−/− hearts. Lipid peroxida
p66Shc−/− mice and perfused under conditions of ischemia and reperfusion. Lipid peroxidat
aging. This increase was not detected in hearts lacking p66Shc. WT, wild-type; N.P., fresh
reperfusion. Values are means±S.E. ⁎pb0.01.60 min. However, under these extreme conditions we could never
detect protection from any substance or intervention.
Due to life span prolongation induced by p66Shc deletion, the
effects of ischemia were compared between hearts from young (4-
month old) and senescent (24-month old) mice. Aging did not modify
the degree of injury in hearts from wt mice as well as the degree of
protection in hearts from p66Shc−/− littermates.
3.2. The absence of p66Shc reduces the degree of oxidative stress caused
by post-ischemic reperfusion
Since excess ROS production is a major cause of injury in ischemic
hearts, oxidative stress was analyzed in WT and p66Shc−/− hearts at
the end of post-ischemic reperfusion. To this aim TBARS formation
was assessed as a marker of lipid peroxidation, whereas the oxidation
of tropomyosin (Tm) was measured as a reliable probe of the
oxidative damage to contractile proteins [34,35].
Fig. 2 illustrates that TBARS formation was increased almost
three-fold in hearts from WT mice subjected to ischemia and
reperfusion independently from the age of the animals. This large
increase in lipoperoxidation was totally abrogated by p66Shc
deletion. In fact, hearts from p66Shc−/− mice displayed TBARS
levels similar to those detected in freshly excised hearts or in
hearts perfused under normoxic conditions. Similarly to what wetion was evaluated as TBARS formation in hearts isolated from young and old WT or
ion was greatly enhanced by post-ischemic reperfusion in WT hearts independently of
ly excised (i.e., non-perfused) hearts; I/R, ischemia (40 min) followed by 15 min of
Fig. 3. Tropomyosin oxidation caused by post-ischemic reperfusion is largely decreased
in hearts isolated from p66Shc−/− mice. In hearts from both young and old WT mice,
post-ischemic reperfusion resulted in tropomyosin oxidation detected as the appear-
ance of higher molecular weight bands due to the formation of disulﬁde cross-bridges
(see Materials and methods and [35]). The degree of tropomyosin oxidationwas largely
reduced in hearts from young and old p66Shc−/−mice. In fact, the density of the higher
molecular weight peptides was not different from those detected in samples from
normoxic hearts (not shown). Molecular weight markers are shown in the ﬁrst lane.
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microembolized pig hearts [34,35], post-ischemic reperfusion-
induced tropomyosin oxidation in WT mouse hearts. This was
detected as the appearance of disulﬁde cross-bridges (DCB) in
immunoblots with anti-tropomyosin antibody carried out after
electrophoresis under non-reducing conditions (Fig. 3). Further
supporting the decrease of oxidative stress in p66Shc−/− hearts,
DCB formation was largely prevented in hearts devoid of p66Shc.Fig. 4. Reperfusion-induced increase in tropomyosin immunoreactivity is signiﬁcantly reduc
an increase in its immunoreactivity against an anti-tropomyosin antibody (CH1 clone). Th
mouse hearts subjected to the I/R protocols described in the previous legends. Panel A illustr
the quantitative analysis of ﬂuorescence carried out on digital images as described in the M
immunoreactivity caused by post-ischemic reperfusion. Also in this case the observed varia
⁎pb0.05.Also in this case the increased oxidation in the WTgroup as well as
the reduced DCB formation in p66Shc−/− hearts were not affected
by aging.In pig and rat hearts, Tm oxidation is reﬂected by an
increase in its immunoreactivity. Therefore, it is possible to
visualize and quantitate the extent of Tm oxidation in cryosections.
Fig. 4 shows that Tm immunoreactivity was signiﬁcantly increased
in reperfused wt hearts as compared to normoxic samples. On the
other hand, the absence of p66Shc prevented the increase in
immunoreactivity occurred during reperfusion. The changes in
immunoreactivity were independent of animal age.
Cardioprotective and antioxidant effects in hearts devoid of p66Shc
could be ascribed to processes occurring in cardiac myocytes or in
non-myocyte elements. This issue cannot be addressed by measuring
ROS formation since the available methodologies do not allow
identifying in which cells of an intact heart these toxic metabolites
are generated. Therefore we analyzed in which heart cells p66Shc is
preferentially expressed. Fig. 5 documents that while other members
of the Shc family are expressed in both myocytes and interstitial cells
of mouse heart, p66Shc is clearly and only expressed in cardiac
myocytes suggesting that ischemia–reperfusion injury is largely
contributed by p66Shc-induced ROS formation within cardiac
myocytes.
3.3. Cardioprotection and antioxidant effects of p66Shc deletion are
comparable to and not additive with those afforded by other antioxidant
or protective interventions
Having demonstrated that the absence of p66Shc protects against
ischemia/reperfusion injury by preventing oxidative stress, the
questions were (i) whether these protective effects are similar to
those elicited by other antioxidant interventions and (ii) whether the
effects of p66Shc deletion can be modiﬁed by the co-administration of
other antioxidants. These issues have never been evaluated so far in
studies characterizing p66Shc. To this aim the results obtained in
p66Shc−/− hearts were compared with those afforded by (i) perfusion
with 1 mM mercaptopropionylglycine (MPG), a well known antiox-
idant [34]; (ii) perfusionwith 0.5 mM pargyline, a MAO inhibitor [37].
Fig. 6 shows that the degree of protection detected as a decrease in
release of LDH in p66Shc−/− hearts was not signiﬁcantly different fromed in hearts isolated from p66Shc−/−mice. The oxidation of tropomyosin is reﬂected by
is antibody was used to stain cryosections from young and old wild-type and p66−/−
ates typical examples of the variations in tropomyosin immunoreactivity. Panel B shows
aterials and methods section. Deletion of p66Shc prevented the increase in tropomyosin
tions were not affected by aging. Values expressed as arbitrary units are means±S.E.
Fig. 5. p66Shc is preferentially expressed in cardiac myocytes. Following collagenase
perfusion (as described in the Materials and methods section), cardiac myocytes were
isolated and separated from interstitial (i.e., non myocyte) cells. Immunoblots were
stained with an anti-Shc antibody that detects the three isoforms of the protein. p66Shc
was only detected in cardiac myocytes. The presence of contaminating cardiomyocytes
in the cardiac interstitial cell fraction by staining with an anti-desmin antibody.
778 A. Carpi et al. / Biochimica et Biophysica Acta 1787 (2009) 774–780that resulting from the other antioxidant interventions. In addition,
the cardioprotection associated with p66Shc absence appeared to be
maximal, since it was not increased by co-administering other
antioxidants. As shown in Fig. 7, also the reduction of oxidative stress
observed in p66Shc−/− was not increased by antioxidant treatments.
In fact, in p66Shc−/− hearts administration of pargyline orMPG did not
modify the decrease in reperfusion-induced Tm oxidation (Fig. 7) or
TBARS formation (results not shown). Finally, the possible involve-
ment of p66Shc in self-endogenous mechanisms of protection was
investigated. In particular, we considered ischemic preconditioning
(IPC), since the powerful protection resulting from this protocol has
been attributed to a slight accumulation of ROS during theFig. 6. Cardioprotection associated with p66Shc ablation is comparable to that afforded
by other antioxidant interventions. Loss of viability was evaluated by measuring LDH
release during reperfusion after 40 min of global ischemia (see also legend to Fig. 1 and
Materials and methods section). For the sake of simplicity only the values related to
coronary efﬂuents are reported. The cardioprotective effect observed in p66Shc−/−
hearts was compared with those afforded by the following interventions: (i) perfusion
with 1mMmercaptopropionylglycine (MPG); (ii) perfusionwith 0.5 mM pargyline that
inhibits monoamine oxidase. The effect elicited by p66Shc ablationwas mimicked by the
other antioxidant interventions. In addition, the degree of protection observed in hearts
devoid of p66Shc was not increased by co-treatment with any other antioxidant. Values
are means±S.E. ⁎pb0.05.preconditioning phase [38]. Therefore, a modest formation of ROS
has been proposed to trigger defense mechanisms that eventually
confer protection against the large burst of ROS formation at the onset
of reperfusion [39]. This concept is supported by the ability of
antioxidants to abrogate IPC protection [40]. Accordingly, also the
decrease in oxidative stress associated with p66Shc deletion might be
expected to counteract the beneﬁcial effects of IPC. Fig. 8 shows that
this was not the case. IPC reduced markedly reperfusion-induced LDH
release, yet this protectionwas not signiﬁcantly different in p66Shc−/−
hearts.
4. Discussion
The present results provide clear evidence that myocardial injury
caused by post-ischemic reperfusion was greatly reduced in hearts
devoid of p66Shc. In particular the absence of this protein involved in
mitochondrial ROS formation prevented the oxidative attack of
structural components of cardiomyocytes, such as lipids and proteins.
The reduced oxidative stress is likely to underlie the maintenance of
tissue viability that was observed in hearts isolated from p66Shc−/−
mice. Indeed, among the many factors contributing to the ischemic
injury p66Shc directly affects only ROS formation.
The present results demonstrate the crucial role of mitochondrial
ROS formation in myocardial I/R injury. In this respect, our ﬁndings
support and complement recent evidence highlighting the role of
MAO [41] and the protection afforded by its inhibition. Interestingly, in
the present study the cardioprotective efﬁcacy due to p66Shc ablationFig. 7. The decrease in reperfusion-induced oxidation of tropomyosin observed in
p66Shc−/− hearts is similar to that afforded by other antioxidant treatments.
Tropomyosin oxidation was evaluated as the appearance of higher molecular weight
bands due to the formation of disulﬁde cross-bridges (see Materials and methods and
legend to Fig. 3). The lane with molecular weight markers separates the left panel
showing typical examples fromWT hearts, whereas samples from p66Shc−/− hearts are
illustrated in the right panel. The protection against tropomyosin oxidation observed in
p66Shc−/− hearts was compared with that afforded by the following interventions: (i)
perfusion with 1 mM mercaptopropionylglycine (MPG); (ii) perfusion with 0.5 mM
pargyline that inhibits monoamine oxidase. The effect elicited by p66Shc ablation was
mimicked by the other antioxidant interventions. In addition, the degree of protection
observed in hearts devoid of p66Shc was not increased by co-treatment with any other
antioxidant.
Fig. 8. p66Shc ablation does not affect cardioprotection by ischemic preconditioning. The protection afforded by ischemic preconditioning (3 cycles of 5 min of ischemia followed by
5 min of reperfusion) was evaluated as a decrease in the release of LDH during post-ischemic reperfusion. The degree of protection was similar to that observed in hearts devoid of
p66Shc in the absence or the presence of ischemic preconditioning. Values are means±S.E. ⁎pb0.05.
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were not additive. Similarly, MAO inhibition does not afford any
additional protection against oxidative stress in ﬁbroblasts devoid of
p66Shc (data not shown). However, at present it is not clear whether
MAO and p66Shc interact to generate ROS or their ﬁnal ROS products
cumulate. On the other hand, it is worth pointing out that MAO
involvement in cardiomyocyte injury has been exclusively referred to
an increased availability of serotonin, an optimal substrate for MAO-A,
due to its massive release from platelets [37,41]. However, in our
model of crystalloid perfused heart MAO inhibition elicited a
signiﬁcant degree of protection in the absence of any increase in
serotonin supply. It is likely that MAO substrates, such as serotonin or
catecholamines are released from endogenous stores under condi-
tions of ischemia and reperfusion.
The degree of protection afforded by p66Shc was also similar to that
obtained with treatment with MPG or IPC. This latter ﬁnding implies
that mitochondrial ROS formation hardly contributes to IPC protec-
tion. However, we wonder whether the involvement of ROS in the
cardioprotective signaling of IPC that has been documented in other
species [40] applies also to mouse heart.
At the end of reperfusion p66Shc−/− hearts displayed a reduced
oxidation of tropomyosin. This ﬁnding might extend the relevance of
p66Shc beyond themaintenance of viability. In fact, we have previously
demonstrated that in microembolized pigs the degree of contractile
impairment is directly correlated to the extent of tropomyosin
oxidation [35]. Therefore, during reperfusion also in cardiomyocytes
that remain viable oxidation of tropomyosin and other myoﬁbrillar
proteins might hamper contractile function. It is tempting to
hypothesize that a reduced oxidation of myoﬁbrillar proteins might
have contributed to the maintained function in p66Shc−/− subjected
to protocols of heart failure [42,43]. In any case, our ﬁndings establish
a direct link between mitochondrial dysfunction and myoﬁlament
oxidation that is likely to contribute signiﬁcantly to several forms of
contractile impairment.
Since p66Shc ablation protects against I/R injury as well as from
other insults, the question might be why cells contain such a
dangerous weapon. Although the physiological roles of p66Shc are
far from being conclusively elucidated, recent studies relate p66Shc-
induced ROS formation to both adipogenesis and immune response. In
particular, p66Shc has been recognized a downstream target of the
insulin signaling pathway, and a critical mediator of insulin-
dependent ROS-upregulation in adipocytes [44]. In its absence,
nutrient storage in the form of triglyceride accumulation along with
thermoinsulation and thermogenesis are likely to be hampered
possibly jeopardizing the growth of young individuals under adverseconditions, such as food restriction or exposure to low temperatures.
On the other hand p66Shc has been shown to prevent excessive
lymphocyte activation that has been observed in p66Shc−/− mice
resulting in the occurrence of a lupus-like autoimmune disease.
Therefore, the loss of this protein appears to hamper immunologic
tolerance favoring systemic autoimmunity [45].
In conclusion, the ﬁndings obtained in mice lacking p66Shc prove
beyond any doubt that mitochondrial ROS formation is not just an
accidental by-product of the respiratory chain, and that most
intracellular oxidative stress originates in mitochondria. However,
and unfortunately, at present the translation of these concepts into
clinical practice is limited by the lack of drugs that prevent ROS
formation by p66Shc.
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